Anti-HPV Ointment (with Iwaki Seiyaku)
Verruca Vulgaris (Common Warts)
Phase 2Completed (Summary results announced in 2025)
Key Facts
Indication
Verruca Vulgaris (Common Warts)
Phase
Phase 2
Status
Completed (Summary results announced in 2025)
Company
About KinoPharma
A clinical-stage biopharma developing novel small-molecule antiviral drugs, with a lead topical treatment for HPV-induced cervical lesions to prevent cervical cancer.
View full company profile